Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.77 |
| ▸ | CA9 | Q16790 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.64 |
| ▸ | TOP2A | P11388 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119724 | 0.99 | CA12 (0.79) | CA12CA9LMNAALDH1A1TSHR | |
| SCHEMBL633421 | 0.97 | CA12 (0.77) | CA12CA9LMNAALDH1A1TSHR | |
| SCHEMBL633327 | 0.88 | CA12 (0.83) | CA12CA9LMNAALDH1A1TSHR | |
| SCHEMBL8752463 | 0.87 | CA12 (1.00) | CA12CA9LMNAALDH1A1TSHR | |
| SCHEMBL14044734 | 0.85 | CA12 (0.74) | CA12CA9LMNAALDH1A1TSHR | |
| SCHEMBL22584911 | 0.81 | LMNA (0.73) | CA12CA9LMNAALDH1A1TSHR | |
| SCHEMBL726433 | 0.80 | CA12 (0.55) | CA12CA9LMNAALDH1A1PKM | |
| SCHEMBL812691 | 0.80 | POLB (0.67) | CA12CA9LMNAALDH1A1PKM | |
| SCHEMBL6792745 | 0.80 | CA12 (0.74) | CA12CA9LMNAALDH1A1TSHR | |
| SCHEMBL22600026 | 0.79 | LMNA (0.70) | CA12CA9LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054056-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2009-05-06 | — | — | EP | claimed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | claimed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | claimed |
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | disclosed |
| EP-2420494-A1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2054056-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | CA12 3442/4885CA9 3038/4885LMNA 4391/4885 |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | CA12 3442/4885CA9 3038/4885LMNA 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.